Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
133 hedge funds and large institutions have $892M invested in Genomic Health, Inc. in 2016 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 38 reducing their positions, and 16 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 38
2% more capital invested
Capital invested by funds: $872M → $892M (+$19.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 134 → 133 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$24.6M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.35M |
| 3 |
Morgan Stanley
New York
|
+$3.19M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$2.94M |
| 5 |
Millennium Management
New York
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.65M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.96M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$2.72M |
| 5 |
CC
Casdin Capital
New York
|
-$2.6M |
GHDX Hedge Fund Activity: Q4 2016 in Review
133 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2016, worth a combined $892M — up 2.3% from $872M a quarter earlier.
Fund positioning in GHDX was balanced in Q4 2016: 16 funds opened new positions, 16 closed out, 53 added to existing stakes and 38 trimmed.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $24.6M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $15.9M sold.
- 133 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2016, down from 134 in Q3 2016.
- Funds reported $892M of Genomic Health, Inc. stock for Q4 2016, up 2.3% quarter-over-quarter.
- 16 funds opened new Genomic Health, Inc. positions in Q4 2016 and 16 closed out, a net change of 0 holders.
- The largest Genomic Health, Inc. buyer in Q4 2016 was Columbia Wanger Asset Management, an estimated $24.6M added.
- The largest Genomic Health, Inc. seller in Q4 2016 was Baillie Gifford & Co, an estimated $15.9M sold.
Based on aggregated 13F filings for Q4 2016.